Vitamin A ( DrugBank: Vitamin A )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎5
53シェーグレン症候群1
90網膜色素変性症5

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01407211
(ClinicalTrials.gov)
April 201114/2/2011Impact of Vitamin A on Gene Expression, in Multiple Sclerosis PatientThe Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis PatientsRelapsing Remitting Multiple SclerosisDietary Supplement: vitamin ATehran University of Medical SciencesNULLEnrolling by invitation20 Years45 YearsBoth30Phase 4Iran, Islamic Republic of
2EUCTR2010-023677-19-IT
(EUCTR)
23/03/201110/06/2011Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 PATIENT WITH RRMS AND SPMS
MedDRA version: 13.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 10029205 - Nervous system disorders
Trade Name: BETAFERON*15CONFEZ 0,25MG/ML+
INN or Proposed INN: Interferon beta-1b
Trade Name: EXTAVIA*SC 15FL 250MCG/ML+15SI
INN or Proposed INN: Interferon beta-1b
Trade Name: DIBASE
INN or Proposed INN: Colecalciferol
AZIENDA OSPEDALIERA S. LUIGI GONZAGANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
3NCT01705457
(ClinicalTrials.gov)
February 20109/10/2012Impact of Vitamin A on RAR Gene Expression in Multiple SclerosisImpact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic PatientsRelapsing Remitting Multiple SclerosisDrug: Dietary Supplement: vitamin A;Drug: placeboTehran University of Medical SciencesNULLEnrolling by invitation20 Years45 YearsBoth20Phase 4Iran, Islamic Republic of
4NCT01417273
(ClinicalTrials.gov)
February 201017/11/2010Impact of Vitamin A on Multiple Sclerosis (MS)Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) PatientsRelapsing Remitting Multiple SclerosisDietary Supplement: vitamin A;Drug: Drug: placeboTehran University of Medical SciencesNULLEnrolling by invitation20 Years45 YearsBoth100Phase 4Iran, Islamic Republic of
5NCT01225289
(ClinicalTrials.gov)
October 20096/9/2010Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis PatientsThe Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple SclerosisRelapsing Remitting Multiple SclerosisDietary Supplement: Vitamin A;Drug: PlaceboTehran University of Medical SciencesNULLCompleted20 Years45 YearsAll36Phase 4Iran, Islamic Republic of

53. シェーグレン症候群


臨床試験数 : 283 薬物数 : 320 - (DrugBank : 101) / 標的遺伝子数 : 56 - 標的パスウェイ数 : 181
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000013234
2014/04/0101/04/2014Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome Dry eye related to chronic GVHD and Sjogren s syndromeDiquafosol sodium and rebamipide ophthalmic solution
Artifical tears, vitamin A ophthalmic solution, or/and sodium hyaluronate ophthalmic solution
Keio University School of MedicineNULLComplete: follow-up complete20years-old75years-oldMale and Female20Not applicableJapan

90. 網膜色素変性症


臨床試験数 : 130 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02465749
(ClinicalTrials.gov)
May 201522/5/2015Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis PigmentosaClinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis PigmentosaRetinitis PigmentosaDrug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tidSun Yat-sen UniversityZhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd.Not yet recruiting18 Years60 YearsBoth404Phase 0China
2NCT00065455
(ClinicalTrials.gov)
July 17, 200323/7/2003Investigating the Effect of Vitamin A Supplementation on Retinitis PigmentosaPilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin ANational Eye Institute (NEI)NULLCompleted18 YearsN/AAll11Phase 1United States
3NCT00346333
(ClinicalTrials.gov)
July 200327/6/2006Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin ARandomized Clinical Trial for Retinitis PigmentosaRetinitis PigmentosaDrug: Lutein;Dietary Supplement: Cornstarch controlNational Eye Institute (NEI)NULLCompleted18 Years60 YearsAll240Phase 3United States
4NCT00000116
(ClinicalTrials.gov)
May 199623/9/1999Randomized Trial for Retinitis PigmentosaRandomized Trial for Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin A;Drug: Nutritional SupplementNational Eye Institute (NEI)NULLCompleted18 Years56 YearsBothPhase 3United States
5NCT00000114
(ClinicalTrials.gov)
May 198423/9/1999Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin E;Drug: Vitamin ANational Eye Institute (NEI)NULLCompleted18 Years49 YearsBothPhase 3NULL